Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211810 | 0.76 | MAOA (0.44) | CYP2A6 | |
| SCHEMBL17211805 | 0.76 | SIRT2 (0.30) | — | |
| SCHEMBL17211813 | 0.72 | CYP26A1 (0.32) | — | |
| SCHEMBL17211822 | 0.71 | KDM1A (0.33) | — | |
| SCHEMBL17211816 | 0.70 | CYP26A1 (0.31) | CYP1A2CYP2C19 | |
| SCHEMBL17211819 | 0.69 | PDE4D (0.31) | — | |
| Ethylene SCHEMBL5831483 | 0.67 | HSD17B3 (0.46) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL353319 | 0.63 | SRD5A1 (0.47) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL14061819 | 0.62 | CYP1A2 (0.51) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL1870205 | 0.60 | PNMT (0.54) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | CYP2A6 724/4885CYP1A2 1228/4885CYP3A4 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.